Want to see MAZE full AI Analyst Report?
Maze Therapeutics, Inc. (MAZE) Stock Statistics & Valuation Metrics
Total Valuation
Maze Therapeutics, Inc. has a market cap or net worth of $1.85B. The enterprise value is $1.41B.
- Market Cap
- $1.85B
- Enterprise Value
- $1.41B
Share Statistics
Maze Therapeutics, Inc. has 55,549,168 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 55,549,168
- Owned by Insiders
- 1.10%
- Owned by Institutions
- 23.36%
Financial Efficiency
Maze Therapeutics, Inc.’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -37.67%.
- Return on Equity (ROE)
- -0.37
- Return on Assets (ROA)
- -0.33
- Return on Invested Capital (ROIC)
- -37.67%
- Return on Capital Employed (ROCE)
- -0.38
- Revenue Per Employee
- 0
- Profits Per Employee
- -929.93K
- Employee Count
- 141
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Maze Therapeutics, Inc. is -11.87. Maze Therapeutics, Inc.’s PEG ratio is 0.23.
- PE Ratio
- -11.87
- PS Ratio
- 90.35
- PB Ratio
- 4.24
- Price to FCF
- -16.91
- Price to Operating Cash Flow
- -18.01
- PEG Ratio
- 0.23
Income Statement
In the last 12 months, Maze Therapeutics, Inc. had revenue of 0 and earned -131.12M in profits. Earnings per share was -3.05.
- Revenue
- 0
- Gross Profit
- -2.40M
- Operating Income
- -142.90M
- Pretax Income
- -131.12M
- Net Income
- -131.12M
- EBITDA
- -128.72M
- Earnings Per Share (EPS)
- -3.05
Cash Flow
In the last 12 months, operating cash flow was -106.54M and capital expenditures -302,000, giving a free cash flow of -106.84M billion.
- Operating Cash Flow
- -106.54M
- Free Cash Flow
- -106.84M
- Free Cash Flow per Share
- -1.81
Dividends & Yields
Maze Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -5.89%
- Earnings Yield
- -6.93%
Stock Price Statistics
- Beta
- 0.96
- 52-Week Price Change
- 7.47%
- 50-Day Moving Average
- 27.48
- 200-Day Moving Average
- 31.53
- Relative Strength Index (RSI)
- 62.20
- Average Volume (3m)
- 675.98K
Important Dates
Maze Therapeutics, Inc. upcoming earnings date is Apr 05, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Apr 05, 2027
- Ex-Dividend Date
- ―
Financial Position
Maze Therapeutics, Inc. as a current ratio of 15.50, with Debt / Equity ratio of 6.57%
- Current Ratio
- 15.50
- Quick Ratio
- 15.50
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.29
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Maze Therapeutics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Maze Therapeutics, Inc. EV to EBITDA ratio is -12.87, with an EV/FCF ratio of -15.65.
- EV to Sales
- 83.60
- EV to EBITDA
- -12.87
- EV to Free Cash Flow
- -15.65
- EV to Operating Cash Flow
- -15.69
Balance Sheet
Maze Therapeutics, Inc. has $411.09M in cash and marketable securities with $60.42M in debt, giving a net cash position of $350.66M billion.
- Cash & Marketable Securities
- $411.09M
- Total Debt
- $60.42M
- Net Cash
- $350.66M
- Net Cash Per Share
- $6.31
- Tangible Book Value Per Share
- $7.68
Margins
Gross margin is 95.28%, with operating margin of -728.06%, and net profit margin of -667.95%.
- Gross Margin
- 95.28%
- Operating Margin
- -728.06%
- Pretax Margin
- -667.95%
- Net Profit Margin
- -667.95%
- EBITDA Margin
- -649.44%
- EBIT Margin
- -658.97%
Analyst Forecast
The average price target for Maze Therapeutics, Inc. is $61.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $61.67
- Price Target Upside
- 89.57% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 10
- Revenue Growth Forecast
- 700.00%
- EPS Growth Forecast
- -50.45%
Scores
- Smart Score
- 5
- AI Score
- 52
